Skip to content
Screener

Reported July 24, 2025 · Before market open

Revenue$766.2MBeat by $40.1M
EPS$1.84Beat by $0.33
Revenue estimate$726.1M
EPS estimate$1.51

Next report

Oct 22, 2026 (in 2 months)
Revenue estimate$825.9M
EPS estimate$2.18

Financials

Q2 2025

Income statement

See full
Revenue$766.5M+9.2%
Gross profit$273.9M+19.1%
Operating income$153.7M+21.8%
Net income$131.8M+18.4%
EPS (diluted)$1.82+20.5%

Balance sheet

See full
Cash & equivalents$509.7M+14.2%
Total debt$308.2M-1.8%
Total equity$2.9B+13.7%
Total assets$4.0B+13.3%

Cash flow

See full
Operating cash flow$177.1M+7.3%
CapEx$75.2M-25.0%
Free cash flow$101.9M+57.3%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$16B-33.9%
Enterprise value$15.8B-34.4%
P/E32.8×-13.3×
P/S5.4×-3.0×

Profitability

See full
Gross margin35.3%-0.4pp
Operating margin19.6%-0.8pp
Net margin16.5%-1.8pp
FCF margin11.6%-0.8pp

Returns & leverage

See full
Return on equity17.7%-2.0pp
Debt / equity0.1×0.0×
Current ratio2.8×+0.4×

Segments

By segment

See full
Proprietary Products$619.8M+10.7%
West Vantage$146.7M

FAQ

When did West Pharmaceutical Services report Q2 2025 earnings?
West Pharmaceutical Services (WST) reported Q2 2025 earnings on July 24, 2025 before market open.
What were West Pharmaceutical Services's Q2 2025 revenue and EPS?
West Pharmaceutical Services reported revenue of $766.2M and eps of $1.84 for Q2 2025.
Did West Pharmaceutical Services beat estimates in Q2 2025?
Revenue beat the consensus estimate of $726.1M by $40.1M. EPS beat the consensus estimate of $1.51 by $0.33.
How did West Pharmaceutical Services's Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 9.1% from $702.0M a year earlier and eps grew 21.1% from $1.52.
Where can I find West Pharmaceutical Services's Q2 2025 SEC filings?
You can read the 8-K earnings release (0000105770-25-000058) and the 10-Q periodic report (0000105770-25-000065) directly on SEC EDGAR. The filing index links above go to sec.gov.